Rhythm Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rhythm Pharmaceuticals Inc (RYTM)
Rhythm Pharmaceuticals Inc stock price live, this page displays NASDAQ RYTM stock exchange data. View the RYTM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rhythm Pharmaceuticals Inc real time stock price chart below.
What Is the Rhythm Pharmaceuticals Inc Stock Price Today?
The Rhythm Pharmaceuticals Inc stock price today is 110.71.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc?
The stock symbol for Rhythm Pharmaceuticals Inc is "RYTM."
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RYTM quote. (ISIN: US76243J1051)
What Is the Rhythm Pharmaceuticals Inc Stock Price Today?
The Rhythm Pharmaceuticals Inc stock price today is 110.71.
What Is the Stock Symbol for Rhythm Pharmaceuticals Inc?
The stock symbol for Rhythm Pharmaceuticals Inc is "RYTM."
What Stock Exchange Does Rhythm Pharmaceuticals Inc Trade On?
Rhythm Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Rhythm Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Rhythm Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RYTM quote. (ISIN: US76243J1051)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
105.13
111.10
52 wk Range
74.50
122.20
RYTM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
105.13111.10
52 wk Range
74.50122.20
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RYTM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
141.47
Upside
+27.78%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
15 Buy
1 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 141.47
(+27.78% Upside)
Rhythm Pharmaceuticals Inc Earnings Call Summary for Q2/2026
- Rhythm posted Q2 loss of $0.73/share vs. $0.81 expected; revenue hit $71.26M, beating $67.53M consensus by 5.52% on strong HO launch momentum.
- IMCIVREE sales rose 19% sequentially to $71.3M; U.S. acquired hypothalamic obesity launch drove growth with 400+ start forms from 300 prescribers.
- Company raised 2026 operating expense guidance to $363M-$397M but cut R&D midpoint by $20M to $175M-$195M due to CMC timing shifts to 2027.
- Management expects Japan launch by year-end 2026, European rollout starting 2027; no GLP-1 step edits required by payers for HO indication to date.
- Shares fell 0.92% premarket to $101.83; company remains unprofitable with $331M cash, sufficient to fund operations for at least 24 months ahead.
Last Updated: 2026/08/04, 15:30
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
-0,73 / -0,81
Revenue / Forecast
71,26M / 67,53M
Compare RYTM to Peers and Sector
Metrics to compare | RYTM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRYTMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −36.3x | −1.4x | −0.4x | |
PEG Ratio | 11.00 | −0.04 | 0.00 | |
Price/Book | 74.0x | 4.5x | 2.6x | |
Price / LTM Sales | 31.8x | 79.8x | 3.0x | |
Upside (Analyst Target) | 32.5% | 83.6% | 51.8% | |
Fair Value Upside | Unlock | 5.7% | 7.2% | Unlock |
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Rhythm Pharma (RYTM) Stock Price Today?
The Rhythm Pharma stock price today is 110,71 USD.
What Stock Exchange Does Rhythm Pharma Trade On?
Rhythm Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rhythm Pharma?
The stock symbol for Rhythm Pharma is "RYTM."
What Is the Rhythm Pharma Market Cap?
As of today, Rhythm Pharma market cap is 7,62B USD.
What Is Rhythm Pharma's Earnings Per Share (TTM)?
The Rhythm Pharma EPS (TTM) is -3,12.
When Is the Next Rhythm Pharma Earnings Date?
Rhythm Pharma will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is RYTM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Rhythm Pharma Stock Split?
Rhythm Pharma has split 0 times.
How Many Employees Does Rhythm Pharma Have?
Rhythm Pharma has 414 employees.
What is the current trading status of Rhythm Pharma (RYTM)?
As of Aug 06, 2026, Rhythm Pharma (RYTM) is trading at a price of 110,71 USD, with a previous close of 110,71 USD. The stock has fluctuated within a day range of 105,13 USD to 111,10 USD, while its 52-week range spans from 74,50 USD to 122,20 USD.
What Is Rhythm Pharma (RYTM) Price Target According to Analysts?
The average 12-month price target for Rhythm Pharma is 141,47 USD, with a high estimate of 160 USD and a low estimate of 105 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +27,78% Upside potential.
What Is the RYTM Premarket Price?
RYTM's last pre-market stock price is 114,14 USD. The pre-market share volume is 300,00, and the stock has decreased by 3,43, or 3,10%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.